Abiomed Inc. announced that they will report Q2, 2010 results on November 05, 2009.

Abiomed Inc., Q2 2010 Earnings Call, Nov-05-2009

Abiomed Inc. announced new clinical data from USpella, the first U.S. multicenter registry of Impella 2.5 patients evaluating the safety and feasibility of left ventricular support with the Impella 2.5 during high-risk percutaneous coronary intervention (PCI) and treatment of acute myocardial infarction (AMI). USpella, presented at TCT 2009 by Brijeshwar Maini, M.D., co-chair, cardiovascular research, interventional cardiologist, Pinnacle Health; attending cardiologist, Moffitt Heart & Vascular Group, evaluated data from 16 Impella 2.5 centers with IRB approval and over 181 patients from the more than 1,000 reported commercial Impella 2.5 cases. The registry examined both high-risk PCI and AMI patients, reporting the following results: High-Risk PCI patient results in USpella: In 64% of the high-risk PCI cases, the patients had been turned down for CABG before treated with Impella 2.5; The high-risk PCI population presented with a more complex anatomy than the SYNTAX trial population (of 23), decreasing SYNTAX score from 38 to 18 after effective revascularization with Impella 2.5; Registry results reaffirmed ejection fraction increases that were similar to PROTECT I results, with improved ejection fraction in USpella high-risk PCI patients increasing from 29 to 34, after Impella 2.5 support; Reported overall MACE was low at 6%; 30-day survival rate was 97%. AMI patient results in USpella: Impella was used after conventional therapies failed, (88% after emergent revascularization; 88% after high-dose inotropes; 68% after IABP therapy); Impella improved hemodynamics in AMI shock patients, improving cardiac index from 1.9 to 2.5 l/min/m2, increasing mean arterial pressure from 62 to 87 mmHg, and decreasing wedge pressure from 28 to 20 mmHg, as well as decreasing overall Systemic Vascular Resistance (SVR); After Impella 2.5 support, overall ejection fraction in AMI patients improved from 29 to 37%; Impella successfully supported AMI refractory shock patients with 69% survival to the next therapy or onto recovery. Also, 58% of AMI shock patients and 89% of AMI patients with no shock were discharged Maini concludes that, 'USpella is the largest IRB registry reported so far for Impella 2.5 that confirms prior positive study results.